Switch to Dolutegravir Regimen Improves Lipid Profile in HIV+ Patients
Investigators performed a randomized, noninferiority, 96-week, strategic trial of dolutegravir to compare efficacy and effect on lipid parameters.
Several studies have determined that PLWHIV have a higher risk for 30-day readmission than the general population.
Dolutegravir monotherapy was noninferior to combination antiretroviral therapy (cART) in patients who started cART during primary HIV infection.
Because of high risk for virologic failure and of the emergence of INSTI resistance, dolutegravir monotherapy should be avoided as a maintenance strategy.